Clinical Study Patient Recruitment Update

RNS Number : 7030B

Destiny Pharma PLC

12 October 2020

 

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Clinical Study Patient Recruitment Update

101 patients recruited in Phase 2b clinical study of lead asset XF-73 for the prevention of post-surgical infections  

Recruitment on track to complete by year-end and report results in Q1 2021

Brighton, United Kingdom - 12 October 2020 - Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections today announces an update on its XF-73 Phase 2b clinical study with 101 patients out of the target of 125 now recruited.

The Phase 2b clinical study is recruiting patients undergoing open heart surgery in United States and Europe. Subject to recruitment being slowed again by the impact of COVID-19, the study is expected to complete recruitment before the end of the year and report results in Q1 2021.

Neil Clark, Chief Executive Officer of Destiny Pharma, said : "We are very pleased to report that we have passed the one hundred patients mark in our lead clinical study testing XF-73 as a novel product preventing the incidence of post-surgical infections. This follows a protocol amendment with the FDA and promising interim safety data announced earlier in the year. We expect to complete recruitment before the end of the year and report results in early 2021 as we start preparations for the Phase 3 study."

Details of Phase 2b Study

The ongoing Phase 2b trial is a multi-centre, randomised, blinded, placebo-controlled study of multiple applications of a single concentration of XF-73 nasal gel to assess the microbiological effect of XF-73 on commensal Staphylococcus aureus nasal carriage in 125 patients scheduled for open heart surgery.

The Phase 2b study design is closely related to the successful 2016 clinical trial, which was funded by the National Institute of Allergy and Infectious Disease (part of the US National Institute of Health) and demonstrated the clinical efficacy of XF-73 versus placebo in reducing nasal Staphylococcus aureus carriage in healthy volunteers.

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[phone]

[e-mail]  

Optimum Strategic Communications

Mary Clark, Shabnam Bashir, Manel Mateus

[phone]

[e-mail]  

finnCap Ltd (Nominated Advisor Joint Broker)

Geoff Nash / Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

WG Partners (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

[phone]

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections.  The company's lead programme is undergoing a Phase 2b clinical trial and is targeting the prevention of post-surgical hospital infections including MRSA. The XF drug candidates are being developed for the prevention and treatment of life-threatening infections caused by antibiotic‑resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organization (WHO) and the United Nations, as well as the G7 and the G20 countries.  Destiny Pharma is also collaborating with SporeGen^® to co-develop a novel, preventative product for COVID-19. For further information, please visit  https://www.destinypharma.com

 

END

 

 

STREAXENEAEEFFA